TH MEDICAL-B

Got it, can I make some money?

$TH MEDICAL-B(02697.HK)🙏🙏🙏

$TH MEDICAL-B(02697.HK) Hope to be healthy and well

$TH MEDICAL-B(02697.HK)

In the screenshot, middle, middle, middle, middle

Let me win once, I haven't won since opening the account.

$TH MEDICAL-B(02697.HK) Post a screenshot and you'll definitely win!!

$ANKER(00668.HK) $LAIFUAL(03952.HK) $TH MEDICAL-B(02697.HK) $XUNLONG SCITECH(06715.HK) $JIANGXI BIO(06915.HK) $ALEBUND-B(09637.HK) $CREALIGHTS(01191.HK) $BAIGE DIGITAL(02672.HK) New stocks again. Public allocation lot sizes for reference, but Anker's discount rate is a bit too low, right? Won't post the calendar, Anker doesn't connect with yesterday's.

🎉【Hot New IPOs】Each Shows Their Strength! Which of These Seven Multi-Sector New IPOs Will Win the First-Day "Gain Champion"?

The recent Hong Kong stock IPO market has been exceptionally lively—covering multiple sectors from AI computing power, robotics black tech, insurtech, to biopharmaceuticals, and even caviar. Who can break through and lead the race first 🧐? Below, Hot Topic brings you to know these seven contenders, with a prize quiz at the end!

$LAIFUAL(03952.HK): A Chinese core component provider for robot precision transmission, ranking second in the industry with a 21.4% market share in harmonic reducer shipments in 2025. 2025 revenue was approximately RMB 261 million, a year-on-year increase of about 143%, with a gross profit margin of about 25.6%. After excluding non-recurring items such as changes in the book value of redeemable liabilities, the operating loss ratio narrowed, and profitability continues to improve.

$TH MEDICAL-B(02697.HK): Focuses on the R&D of percutaneous puncture and ablation surgical robots. Its core product, the puncture robot, has obtained Class III registration certificates from the NMPA for all four models. 2025 revenue was approximately RMB 12 million, with a gross profit margin maintained at about 76%; the company continues to invest in R&D to advance product commercialization and is not yet profitable.

$JIANGXI BIO(06915.HK): Jiangxi Biological is one of the few global anti-serum enterprises to achieve full industry chain integration, at the forefront of quality improvement and technological upgrading in the industry. Revenue over the past three years increased from approximately RMB 198 million to RMB 235 million, showing sustained and steady growth. The gross profit margin before fair value adjustment rose from 75.2% to 82.5%, and annual profit grew for three consecutive years to RMB 95 million.

$XUNLONG SCITECH(06715.HK): The world's largest caviar enterprise, the company has ranked first in global caviar sales for 11 consecutive years since 2015. Revenue over the past three years increased from approximately RMB 577 million to RMB 769 million, showing sustained and steady growth. The company's operating profitability is outstanding, with annual profit growing for three consecutive years.

$BAIGE DIGITAL(02672.HK): An insurtech company providing technology-enabled insurance intermediary services to scenario partners and insurance companies, with a core focus on distributing scenario insurance products to end policyholders. 2025 revenue was RMB 1.23 billion, with gross profit of RMB 103 million. Both revenue and gross profit have grown for three consecutive years. The company is still in a growth investment phase and is not yet profitable.

$ALEBUND-B(09637.HK): A biopharmaceutical company that has developed differentiated and effective therapies targeting the world's largest kidney disease indications. 2025 revenue was approximately RMB 31 million, a year-on-year increase of about 368%, with the gross profit margin improving to 44.0%. The company continues to increase R&D investment and is still in the R&D investment and commercialization ramp-up stage.

$CREALIGHTS(01191.HK): A provider of photoelectric interconnection products, offering optical modules, AOCs, and other products. Its photoelectric interconnection products are widely used in AI data centers to support high-speed, high-density, and high-energy-efficiency data transmission. Revenue over the past three years increased from approximately RMB 175 million to RMB 1.221 billion. The gross profit margin turned positive from negative in 2023 and stabilized at about 9%, with the profit structure continuously improving.

🎯 Prize Quiz | Which of the Seven New IPOs Can Lead the Race?

Among these seven hot new IPOs, whose explosive potential are you most bullish on?

How to Participate: Leave your prediction for the first-day gain champion + your reasoning in the comments section.

Reward: Users who successfully predict the result will receive 500 mission coins!

Public placement hand count, for reference

$JIANGXI BIO(06915.HK) $XUNLONG SCITECH(06715.HK) $LAIFUAL(03952.HK) $TH MEDICAL-B(02697.HK) $ALEBUND-B(09637.HK) $BAIGE DIGITAL(02672.HK) $CREALIGHTS(01191.HK) $CFMEE(09630.HK) $MERDEKAGOLD-DRS(06228.HK) $SG MICRO(03661.HK) $KEYTOP PARKING(02272.HK) $WENGE AI(01956.HK) $LINGYI ITECH(01688.HK)